Febrile neutropenia resident survival guide: Difference between revisions
No edit summary |
No edit summary |
||
Line 132: | Line 132: | ||
❑ In clinic or hospital setting | ❑ In clinic or hospital setting | ||
❑ Observe for 4-24 hours after drug administration</div>|H02='''Hospitalize the patient'''}} | ❑ Observe for 4-24 hours after drug administration</div>|H02='''Hospitalize the patient'''}} | ||
{{familytree | | | | {{familytree | | | | |)|-|.| | | |!| | | |}} | ||
{{familytree | | | | {{familytree | | | | |!| I01 | | I02 | | |I01= <div style="float: left; text-align: left; line-height: 150% ">'''Consider continuing with inpatient IV antibiotics:'''<br> | ||
❑ Inability to tolerate oral medications<br> | ❑ Inability to tolerate oral medications<br> | ||
❑ Unavailabilty of telephone, transportation to hospital, caregiver<br> | ❑ Unavailabilty of telephone, transportation to hospital, caregiver<br> | ||
Line 146: | Line 146: | ||
'''or'''<br> | '''or'''<br> | ||
❑ [[Imipenem-cilastatin]]</div>}} | ❑ [[Imipenem-cilastatin]]</div>}} | ||
{{familytree | | | | {{familytree | | | | |!| |)|-|-|-|(| | | |}} | ||
{{familytree | | | {{familytree | | | | | J01 | | | J02 | | | |J01=<div style="float: left; text-align: left; line-height: 150% ">'''Consider discharge with outpatient oral antibiotics:'''<br> | ||
❑ Ability to tolerate oral medications<br> | ❑ Ability to tolerate oral medications<br> | ||
❑ Availabilty of telephone, transportation to hospital, caregiver<br> | ❑ Availabilty of telephone, transportation to hospital, caregiver<br> | ||
Line 170: | Line 170: | ||
<tr><td>❑ [[KPCs]]</td><td>❑ [[Polymyxin-colistin]]<br>'''or'''<br>❑ [[Tigecycline]]</td></tr> | <tr><td>❑ [[KPCs]]</td><td>❑ [[Polymyxin-colistin]]<br>'''or'''<br>❑ [[Tigecycline]]</td></tr> | ||
</table></div>}} | </table></div>}} | ||
{{familytree | | |!| | | | | | | | | | | |}} | {{familytree | | | | | |!| | | | | | | | | | | |}} | ||
{{familytree | | K01 | | | | | | | | | | |K01=<div style="float: left; text-align: left; line-height: 150% ">'''Followup:'''<br> | {{familytree | | | | | K01 | | | | | | | | | | |K01=<div style="float: left; text-align: left; line-height: 150% ">'''Followup:'''<br> | ||
❑ Vigilant observation for recovery<br> | ❑ Vigilant observation for recovery<br> | ||
❑ Ensure 24 hours a day and 7 days a week access to the appropriate medical care<br> | ❑ Ensure 24 hours a day and 7 days a week access to the appropriate medical care<br> |
Revision as of 01:04, 9 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Synonyms and keywords:
Definition
Neutropenic fever is defined as one oral temperature of ≥38.3°C (101°F) or a temperature of ≥38.0°C (100.4°F) for over one hour. Neutropenia is defined as an absolute neutrophil count (ANC) <500 cells/mm3 or an ANC that is expected to become less than 500 cells/mm3 over the next 48 hours. Profound neutropenia is defined as an ANC <100 cells/mm3. Patients with functional neutropenia have a qualitative abnormality of neutrophil functions despite a normal or elevated ANC, as seen in hematological malignancy, and are at increased risk of infections similarly to patients with low ANC.[1]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Management
Initial Management
Characterize the symptoms: Symptom suggestive of neutropenic fever:
with
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consider the diagnosis of neutropenic fever POTENTIALLY LIFE THREATENING | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Obtain a detailed history: ❑ History of any symptom of infections and inflammation of
❑ History of any co-morbid conditions
❑ History of any recent exposure to infections | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Search for signs of infections at
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests (routine): ❑ CBC with
❑ BMP
❑ Urinalysis Order additional tests (not routine and order if clinically indicated):
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do a risk assessment using MASCC risk Index: (MANDATORY)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Low risk patients: ❑ MASCC score ≥21 or ❑ Expected brief neutropenia (≤7 days) | High risk patients: ❑ MASCC score <21 or ❑ Expected prolonged neutropenia (>7 days) Patients who do not strictly fulfill the criteria for being at low risk Afebrile neutropenic patients with new signs or symptoms suggestive of infection | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administer oral or IV empirical broad-spectrum antibiotic therapy (URGENT): ❑ Ciprofloxacin + Amoxicillin-clavulanate | Hospitalize the patient | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consider continuing with inpatient IV antibiotics: ❑ Inability to tolerate oral medications | Administer IV empirical antipseudomonal antibiotic monotherapy (URGENT): ❑ Cefepime | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Consider discharge with outpatient oral antibiotics: ❑ Ability to tolerate oral medications | Add vancomycin to the initial empirical antibiotic monotherapy for: ❑ Suspected Catheter related infection Consider modifying the initial empirical antibiotic monotherapy for:
or
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Followup: ❑ Vigilant observation for recovery
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Management 2 to 4 Days After Initiation of Antibiotic Treatment
Do's
- Modify the antibiotic regimens depending on the clinical picture and the epidemiology of infections in the area and the hospital where the patient is being treated at.
Don'ts
- Don't measure the temperature of the patient in the axillary area because it is not as specific as if it was taken orally.
- Don't measure the temperature of the patient rectally to avoid contaminating the skin and soft tissues of the rectal area.
References
- ↑ Freifeld, AG.; Bow, EJ.; Sepkowitz, KA.; Boeckh, MJ.; Ito, JI.; Mullen, CA.; Raad, II.; Rolston, KV.; Young, JA. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–93. doi:10.1093/cid/cir073. PMID 21258094. Unknown parameter
|month=
ignored (help)